Archives
-
MAPK10–KRT16 Axis in NSCLC Metastasis
2026-10-07
A 2026 study identifies MAPK10 as a metastasis-suppressive kinase that phosphorylates KRT16, enabling RNF213-mediated ubiquitination and proteasomal degradation. Cellular, animal, and clinical observations support the MAPK10–KRT16–RNF213 pathway as a mechanistic framework and candidate prognostic axis, although broader validation is still required.
-
NF449 Selective P2X1 Blockade in Platelet Thrombosis
2026-10-06
Hechler and colleagues used NF449 to distinguish the contribution of platelet P2X1 from P2Y1 and P2Y12 signaling in human platelet responses and mouse thrombosis models. The study supports P2X1 as a modifiable component of platelet activation, while its dose-dependent loss of selectivity and limited bleeding assessment define important boundaries for interpretation.
-
ANGPTL4-IQGAP1 Axis in Prostate Cancer Chemoresistance
2026-10-06
Zhuang and colleagues report that cancer-associated fibroblasts promote prostate cancer chemoresistance by secreting ANGPTL4, engaging IQGAP1, and activating a Raf–MEK–ERK–PGC1α program linked to mitochondrial biogenesis and oxidative phosphorylation. The study provides a mechanistic model for non-cell-autonomous drug resistance, while its mainly preclinical evidence leaves questions about patient-level validation and therapeutic translation.
-
Silybin A Research: Evidence, Uses and Limits
2026-10-05
A source-grounded overview of Silybin A and Silymarin research, separating supplier claims from published evidence and explaining why findings for praeruptorin A cannot be directly applied to Silybin A.
-
Plant Cell Lysis Buffer: Evidence and Scope
2026-10-05
This overview answers five questions about how Plant Cell Lysis Buffer is described, what evidence supports its intended applications, and how those claims relate—or do not relate—to a separate NSCLC study of the MAPK10–KRT16 pathway. It distinguishes supplier information from peer-reviewed findings and identifies important limits on interpretation.
-
Z-VAD-FMK in Apoptosis and Necroptosis Research
2026-10-03
A source-grounded overview of Z-VAD-FMK, covering its reported caspase-inhibitory profile, conceptual uses in apoptosis inhibition and cell-death research, relevance to necroptosis studies, evidence strength, and important limitations in interpreting broad caspase blockade.
-
Epoxomicin Workflows for Proteasome Studies
2026-10-02
Epoxomicin combines nanomolar potency with irreversible, chymotrypsin-like proteasome inhibition for clean pathway perturbation. This guide translates that mechanism into protein degradation assays, RIPK3-centered inflammation studies, and disease-model workflows with practical controls and troubleshooting.
-
Tranexamic Acid Workflows for Clot Stability
2026-10-01
Tranexamic Acid gives researchers a concentration-controlled way to study inhibition of fibrinolysis, clot persistence, and plasmin-driven cell responses. This practical guide connects biochemical assays with a 2024 bi-layer wound-dressing study while separating validated findings from workflow recommendations.
-
MLN4924 HCl salt: Applied Research Workflows
2026-10-01
MLN4924 HCl salt provides a practical chemical route to interrogate NAE-dependent cullin-RING ligase activity, protein turnover, and cell fate. This guide connects robust assay design with the reference study’s viral RIPK3-degradation mechanism while clearly separating established biology from application-focused recommendations.
-
Asunaprevir (BMS-650032): HCV NS3 Guide
2026-09-30
Asunaprevir, also called BMS-650032, is a potent oral HCV NS3/4A protease inhibitor with a supplier-listed biochemical IC50 of 1 nM. This guide distinguishes enzyme inhibition, cellular HCV RNA replication inhibition, genotype coverage, formulation constraints, and research-use limitations.
-
Betaine hydrochloride for inflammasome assays
2026-09-30
Betaine hydrochloride provides a water-soluble, high-purity variable for metabolic enzyme research, protease assays, and carefully controlled cell-based experiments. This guide translates an inflammation-focused esophageal cancer study into practical assay design while separating literature findings from exploratory reagent workflows.
-
TCEP Hydrochloride for Capture-and-Release LFAs
2026-09-29
TCEP hydrochloride provides a water-soluble, thiol-free route for testing disulfide-triggered release in high-sensitivity lateral flow assays. This article translates the AmpliFold concept into an executable workflow while showing how the same reagent supports protein digestion enhancement, hydrogen-deuterium exchange analysis, and other reduction strategies.
-
PSMD14–CARM1 Signaling in Hepatocellular Carcinoma
2026-09-29
The reference study identifies a PSMD14–CARM1–FERMT1 axis that promotes hepatocellular carcinoma proliferation and metastasis through CARM1 stabilization and H3R17 dimethylation. Its combination of patient data, cellular and animal models, mechanistic chromatin analysis, and pharmacological inhibition provides a framework for studying how deubiquitination and histone arginine methylation cooperate in HCC.
-
T0070907: A Precision PPARγ Antagonist Workflow
2026-09-28
T0070907 is a covalent, high-affinity PPARγ antagonist for separating receptor-dependent transcription from downstream cellular phenotypes. This workflow connects reporter assays, adipogenesis inhibition, RXRα/PPARγ pathway testing, and carefully controlled cancer cell-cycle studies.
-
Phosphorylation Fidelity in Insulin Signaling Research
2026-09-28
A mechanistic guide to using Sodium Orthovanadate to preserve tyrosine phosphorylation in insulin-signaling experiments—while accounting for its broad enzyme activity, assay limits, and translational boundaries.